HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Tom Treasure Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Treasure, T. Search for Related Content PubMed Articles by Treasure, T. Related Collections Education Professional affairs

Reviews

Are randomised trials needed in the era of rapidly evolving technologies?

Clinical Operational Research Unit, Department of Mathematics, UCL, London WC1H 0BT, United Kingdom

Received 19 June 2008; accepted 26 August 2008.

^_* Corresponding author. Tel.: +44 7957 168754. (Email: tom.treasure{at}gmail.com).

New technologies are expensive. The health care budget cannot expand indefinitely so if new treatments are introduced they may have to displace other treatments, or prevent other new treatments coming into practice. This is not simply a money saving exercise; it is accepted that new high technology treatments may cost more to implement but they must be worth the money spent in comparison with other treatments. Therefore cardiothoracic surgeons must first demonstrate that our treatments are effective. Then we need evidence of cost effectiveness in comparison with other therapies.

Key Words: Evidence based medicine • Clinical trials • Innovation • Emerging technology

This article has been cited by other articles:

				K. Moghissi Editorial comment: Are randomised trials needed in the era of rapidly evolving technologies? Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 478 - 479. [Full Text] [PDF]